Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV

Gynecologic Oncology

Volumn 140, Issue 2, 2016, Pages 215-220

  Ataseven, Beyhan ^a   Grimm, Christoph ^a,b   Harter, Philipp ^a   Heitz, Florian ^a   Traut, Alexander ^a   Prader, Sonia ^a   Du Bois, Andreas ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Debulking surgery; FIGO IV ovarian cancer; Overall survival; Residual tumor

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SYSTEMIC THERAPY; COHORT ANALYSIS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951751455     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.12.007     Document Type: Article

References (22)

1. Robert-Koch-Institut Krebs in Deutschland Häufigkeiten und Trends 2013 Robert-Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister (http://www.rki.de)
2. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
3. P. Harter, Z.M. Muallem, C. Buhrmann, D. Lorenz, C. Kaub, R. Hils, and et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer Gynecol. Oncol. 121 2011 615 619
4. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, W.T. Creasman, and et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer Int. J. Gynaecol. Obstet. 95 Suppl. 1 2006 S161 S192
5. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J. Clin. Oncol. 20 2002 1248 1259
6. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 47 1992 159 166
7. S.J. Chang, M. Hodeib, J. Chang, and R.E. Bristow Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol. Oncol. 130 2013 493 498
8. R.E. Bristow, F.J. Montz, L.D. Lagasse, R.S. Leuchter, and B.Y. Karlan Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer Gynecol. Oncol. 72 1999 278 287
9. J.P. Curtin, R. Malik, E.S. Venkatraman, R.R. Barakat, and W.J. Hoskins Stage IV ovarian cancer: impact of surgical debulking Gynecol. Oncol. 64 1997 9 12
10. P. Wimberger, M. Wehling, N. Lehmann, R. Kimmig, B. Schmalfeldt, A. Burges, and et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group) Ann. Surg. Oncol. 17 2010 1642 1648
11. W.E. Winter 3rd, G.L. Maxwell, C. Tian, M.J. Sundborg, G.S. Rose, P.G. Rose, and et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 26 2008 83 89
12. D.S. Chi, C.C. Franklin, D.A. Levine, F. Akselrod, P. Sabbatini, W.R. Jarnagin, and et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach Gynecol. Oncol. 94 2004 650 654
13. J. Prat Staging classification for cancer of the ovary, fallopian tube, and peritoneum Int. J. Gynaecol. Obstet. 124 2014 1 5
14. B. Ataseven, C. Grimm, P. Harter, S. Prader, A. Traut, F. Heitz, and et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer Gynecol. Oncol. 2014
15. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann. Surg. 240 2004 205 213
16. J.M.T. Janco, G. Glaser, B. Kim, M.E. McGree, and A.L. Weaver Cliby WA, et al Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol. Oncol. 138 2015 70 77
17. C. Escayola, G. Ferron, M. Romeo, J.J. Torrent, and D. Querleu The impact of pleural disease on the management of advanced ovarian cancer Gynecol. Oncol. 138 1 2015 216 220
18. N.R. Gomez-Hidalgo, B.A. Martinez-Cannon, A.M. Nick, K.H. Lu, A.K. Sood, R.L. Coleman, and et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care Gynecol. Oncol. 2015
19. F. Heitz, D. Ognjenovic, P. Harter, S. Kommoss, N. Ewald-Riegler, M. Haberstroh, and et al. Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications Int. J. Gynecol. Cancer 20 2010 41 46
20. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system Gynecol. Oncol. 105 2007 84 89
21. N.S. Horowitz, A. Miller, B. Rungruang, S.D. Richard, N. Rodriguez, M.A. Bookman, and et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 J. Clin. Oncol. 33 2015 937 943
22. R. Eitan, H. Krissi, H. Levavi, G. Sabah, and Y. Peled Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention PLoS One 8 2013 e55645